Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Koeberle A et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. 2010 J. Pharmacol. Exp. Ther. pmid:19934399
Armstrong PC et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. 2010 J. Thromb. Haemost. pmid:19995405
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Dragani A et al. Clinical and laboratory phenotype associated with the aspirin-like defect. 2010 Br. J. Haematol. pmid:19814736
Parmar JH et al. Significant prostacyclin/thromboxane level imbalance after lower limb arterial angioplasty: a possible platelet function alteration. 2010 J Vasc Interv Radiol pmid:20800778
Kawabata K et al. Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction. 2010 J. Cardiovasc. Pharmacol. pmid:20625313
Würtz M et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. 2010 JACC Cardiovasc Interv pmid:20723855
Kim SY et al. Platelet anti-aggregation activities of compounds from Cinnamomum cassia. 2010 J Med Food pmid:20828311
Bao YM et al. [Effect of precondition with GBE50 and Salviae miltionrrhizae on cycloxygenase-2 and its downstream effectors contents in ischemia/reperfusion myocardium]. 2010 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:21066890
De la Cruz JP et al. Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood. 2010 Anesth. Analg. pmid:21048099
Renda G et al. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. 2010 Haematologica pmid:21123440
Iagoda AV and Gladkikh NN [Thromboxane-prostacyclin balance and platelet aggregability in patients with minor cardiac abnormalities]. 2010 Ter. Arkh. pmid:21086621
Huang HC et al. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. 2010 J. Gastroenterol. Hepatol. pmid:20659230
Wang BZ et al. [Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang]. 2010 Zhonghua Yu Fang Yi Xue Za Zhi pmid:21215134
Ge Y et al. [Effect of ulinastatin on thromboxane Bâ‚‚ and deep vein thrombosis in elderly patients after hip joint replacement]. 2010 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:21200097
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Canales A et al. The effect of consuming meat enriched in walnut paste on platelet aggregation and thrombogenesis varies in volunteers with different apolipoprotein A4 genotype. 2010 Sep-Oct Nutr Hosp pmid:21336431
Oviedo PJ et al. Progestogens reduce thromboxane production by cultured human endothelial cells. 2011 Climacteric pmid:20443717
Sambu N et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. 2011 Heart pmid:21795297
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Hoh CM et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. 2011 Am. J. Vet. Res. pmid:21801060
Dalli E et al. Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. 2011 Thromb. Res. pmid:21737127
Gao F et al. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. 2011 Chin. Med. J. pmid:21740787
Lukasik M et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. 2011 Thromb. Res. pmid:21788065
Shen L et al. In vivo oxidation, platelet activation and simultaneous occurrence of natural immunity in atherosclerosis-prone mice. 2011 Isr. Med. Assoc. J. pmid:21845968
Mattiello T et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. 2011 J. Am. Coll. Cardiol. pmid:21816313
Ramadan E et al. Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats. 2011 Neuropharmacology pmid:21839100
Lomakin NV and Gruzdev AK [Cyclooxygenase inhibitors and antiplatelet effect of acetylsalicylic acid. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice]. 2011 Kardiologiia pmid:21878085
Zhu F et al. [Experimental study on anti-inflammatory and analgesic effects of electroacupuncture combined with medium frequency therapy in model rats with lumbar nerve root compression]. 2011 Zhongguo Zhen Jiu pmid:21894700
Wójtowicz A et al. Aspirin resistance may be associated with adverse pregnancy outcomes. 2011 Neuro Endocrinol. Lett. pmid:21670728
Graziani F et al. Thromboxane production in morbidly obese subjects. 2011 Am. J. Cardiol. pmid:21439532
Cathcart MC et al. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. 2011 Mol. Cancer pmid:21388528
Oh SH et al. Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. 2011 Pharmacogenomics pmid:21449675
Akagi Y et al. Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats. 2011 Biol. Pharm. Bull. pmid:21415533
Capodanno D et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. 2011 Circ Cardiovasc Interv pmid:21386092
Lynch CM et al. The role of thromboxane A(2) in the pathogenesis of intrauterine growth restriction associated with maternal smoking in pregnancy. 2011 Prostaglandins Other Lipid Mediat. pmid:21723954
Yan LG et al. Injectable caltrop fruit saponin protects against ischemia-reperfusion injury in rat brain. 2011 Am. J. Chin. Med. pmid:21476209
Liu JQ et al. Effects of tanshinone IIA, a major component of Salvia miltiorrhiza, on platelet aggregation in healthy newborn piglets. 2011 J Ethnopharmacol pmid:21453766
Halawani SH et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. 2011 Thromb. Haemost. pmid:21544317
Gonçalves LH et al. Urinary 11-dehydro thromboxane B₂ levels in type 2 diabetic patients before and during aspirin intake. 2011 Clin. Chim. Acta pmid:21510926
Bauer J et al. Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. 2011 Biochem. Pharmacol. pmid:20933508
Basselin M et al. Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites. 2011 Neurochem. Res. pmid:20981485
Oates JC et al. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. 2011 Am. J. Med. Sci. pmid:20924284
Grove EL et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. 2011 J. Thromb. Haemost. pmid:20955349
Trostchansky A et al. Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2. 2011 J. Biol. Chem. pmid:21266582
Basselin M et al. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. 2011 J. Cereb. Blood Flow Metab. pmid:20664612
Ceprnja M et al. Oxidative stress markers in patients with post-traumatic stress disorder. 2011 Coll Antropol pmid:22397253
Toliopoulos IK et al. Inhibition of platelet aggregation and immunomodulation of NK lymphocytes by administration of ascorbic acid. 2011 Indian J. Exp. Biol. pmid:22403863
Hong F et al. Protective effect of Shenfu injection on thromboangiitis obliterans model rats. 2011 J Ethnopharmacol pmid:21982791
Lordkipanidzé M et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. 2011 Int. J. Cardiol. pmid:20207433